AHAustin Hoke

Austin Hoke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Austin Hoke has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Adam J. Kimple

    Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel, North Carolina, United States

    1 shared publication
  • Adam M. Zanation

    Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel, North Carolina, United States

    1 shared publication
  • Alexander Langerman

    Department of Otolaryngology–Head and Neck Surgery Vanderbilt University Medical Center Nashville Tennessee USA

    1 shared publication
  • Asha Sarma

    Department of Radiology Vanderbilt University Medical Center Nashville Tennessee USA

    1 shared publication
  • Barbara A. Murphy

    Department of Medicine, Division of Hematology and Oncology Vanderbilt University Medical Center Nashville Tennessee USA

    1 shared publication
  • Brent A. Senior

    Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel, North Carolina, United States

    1 shared publication

Latest Publications

  • Open Access

    Neoadjuvant Cemiplimab for Resectable Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series

    by Whitney Jin, Ryan K. Rigsby, Kim Ely, Austin Hoke, Robert Sinard, Kyle Mannion, Jill Gilbert, Lindsay Mundy, Alexander Langerman, Sarah Rohde, et al.

    Introduction: A Phase II trial demonstrated that neoadjuvant cemiplimab was associated with pathologic complete response (pCR) in 51% of patients with locoregionally advanced cutaneous squamous cell carcinoma (cuSCC). We evaluated real‐world radiographic and pathologic responses to neoadjuvant cemiplimab and assessed radiologic–pathologic concordance. Methods: Retrospective single‐institution cohort study including 18 patients with locoregionally advanced head and neck cuSCC treated with neoadjuvant cemiplimab before curative‐intent surgery between 2019 and 2024. Pathologic and radiographic responses were assessed using pathology review and RECIST 1.1/iRECIST. Results: pCR occurred in 11 patients (61%) and major pathologic response (MPR) in 2 (11%), yielding a 72% combined pathologic response rate. Among 16 patients with evaluable imaging, only 33% demonstrated radiographic partial response (PR), and none achieved radiographic complete response. Radiologic response frequently underestimated tumor clearance. Conclusions: Neoadjuvant cemiplimab produced high pathologic response rates in real‐world practice, while RECIST‐based imaging underestimated true tumor response, highlighting limitations of anatomic imaging in immunotherapy‐treated cuSCC.


  • Open Access

    Multisite Head and Neck Pediatric Posttransplant Lymphoproliferative Disorder: A Case Report

    by Lily Gao, Austin Hoke, Jarrett Jackson, Laura Petrauskas, Emily F. Mason, Asha Sarma, Debra Friedman, David Bearl, Daniel Dulek, Christopher Wootten, et al.

    Posttransplant lymphoproliferative disorder (PTLD) can mimic infectious processes in the head and neck. A high index of suspicion for PTLD must be maintained in pediatric transplant patients, and minimal response to antibiotics/corticosteroids should prompt timely biopsy of suspicious tissue to expedite the diagnosis and treatment of PTLD.

  • Postoperative Pain Management and Perceived Patient Outcomes following Endoscopic Pituitary Surgery

    by Austin Thomas-Kim Hoke, Madison J Malfitano, Adam M. Zanation, Charles S. Ebert, Brent A. Senior, Adam J. Kimple, Brian D. Thorp

    Objectives Pain management remains a point of emphasis given the ongoing opioid crisis. There are no studies in the literature interrogating opioid prescribing and use following endoscopic pituitary surgery. This study investigates provider prescribing tendency, patient utilization of analgesics, and patient outcomes regarding pain management after endoscopic pituitary surgery.Methods We identified 100 patients undergoing endoscopic pituitary surgery at one institution from 2016 to 2018 in the electronic medical record (EMR) and state narcotic database to determine postoperative analgesic regimens. A telephone survey was used to characterize postoperative analgesic use and satisfaction with prescribed regimen.Results Fifty-two different pain control regimens were prescribed to the study patients. Also, 93% of study patients were prescribed an opioid postoperatively. The average quantity of opioids prescribed per patient in morphine milligram equivalents (MMEs) was 625 (equivalent 83 oxycodone 5-mg tablets) with an average MME/day of 59 (equivalent 8 oxycodone 5-mg tablets). A total of 71% survey respondents who used opioids reported using 50% of their postoperative opioid intake in the first 24 to 48 hours after discharge. There were no significant differences in pain outcome between opioid users and nonopioid users.Conclusion Vast heterogeneity exists in narcotic prescribing by providers at our institution following endoscopic pituitary surgery. Narcotic prescribing patterns exceeded most patients' analgesic needs. Opioid analgesics were not superior to nonopioids regimens in patient-reported pain outcomes in this study population.